.png)
Most people learn about Borrelia through the same storyline: a tick bite, a rash, then symptoms. That storyline is common, and it’s the one our testing and guidelines are built around.
Pregnancy adds a different layer. A placenta is not just a passive filter. It’s living tissue. It has blood flow, immune signaling, and a constant exchange between mother and developing baby. In several infections we already understand well, pregnancy changes how we think about exposure and risk.
Borrelia sits in a gray zone here. It has been found in placental and fetal tissues in case reports over the years. At the same time, there are still no widely used diagnostic guidelines for “congenital Borrelia,” and there aren’t large studies that track outcomes long-term. That’s why the question keeps coming back.
A newly published 2026 case report in the journal Microorganisms brings this to life in a very practical way. It’s one case, so it doesn’t tell us how often this happens. What it does show is how complicated the real-world picture can be, especially when we rely mainly on antibody tests.
What happened in this case
Researchers studied a mother and her child who both had symptoms over time that led to Borrelia testing. Their results didn’t fit neatly into the standard “positive vs negative” boxes.
The most important detail: the team didn’t rely on a single test. They used several different ways of looking for Borrelia, some of which look for the immune response, and others that look for the organism itself.
Here’s what makes the case so interesting:
- Placental tissue from the birth was saved, and years later the researchers went back and examined it. They were able to stain the tissue and visually identify a spirochete-shaped organism that reacted to Borrelia-specific antibodies under advanced microscopy.
- They also extracted DNA from that same archived placental tissue and found Borrelia DNA using PCR (a method that looks for genetic material).
- Later on, the researchers reported culturing live spirochetes from a vaginal swab from the mother and from the child’s urine. Culture is significant because it suggests something living was present in those samples at the time they were collected.
- When they looked at genetic sequences, the Borrelia identified in both mother and child matched Borrelia burgdorferi sensu stricto, the main North American species.
Meanwhile, the antibody story stayed confusing:
Both mother and child showed some signs of immune reactivity on various tests over the years, yet neither consistently met the conventional two-tier criteria that many clinicians are taught to treat as the deciding standard.
That mismatch is one of the core points of the paper.
Why the antibody issue matters
Most routine Lyme testing looks for antibodies, which are proteins your immune system makes after it recognizes an infection. For many infections, antibody testing is useful and reliable.
In real life, antibody results can vary for several reasons:
- timing (early or fluctuating infection)
- immune system differences from person to person
- prior antibiotic exposure
- the immune changes that come with pregnancy
- strain differences
This case report highlights something that families experience often: symptoms and biology can be messy, and the testing framework is sometimes too rigid for that mess.
Why this question is still understudied
This is not a simple study to run.
To truly answer “how often does congenital transmission happen,” researchers would need to follow large numbers of pregnancies over time, with standardized sampling and careful long-term follow-up. They’d need to test mothers, babies, and placentas using a mix of methods that can detect low levels of organisms without confusing contamination for true infection.
That kind of work is expensive, complex, and slow. The result is a gap: families and clinicians are left making decisions with limited data.
What this paper does and does not prove
This is important to say clearly, in plain language.
This paper does not prove congenital transmission is common.
It also does not prove that every child with chronic symptoms has an in-utero Borrelia exposure.
What it does show is that:
- placental involvement can be detectable years later when the right methods are used
- mother and child can share the same Borrelia species and strain features
- standard antibody testing can fail to capture the full picture in some cases
And it makes a strong argument that congenital transmission deserves more serious research attention, because the diagnostic and clinical implications are real.
A calmer takeaway
If you’re a parent reading this, the goal is not alarm. The goal is clarity.
Pregnancy is a unique immune and biologic setting. When a paper shows Borrelia signals in archived placenta plus matching findings in a child later on, it’s a reminder that “we don’t know enough” is sometimes the most honest statement in medicine.
The next step isn’t fear. It’s better research, better diagnostic pathways, and a more thoughtful conversation about how infections may enter a child’s story long before a tick bite is ever noticed.